Propel FDA Approval History
FDA Approved: Yes (First approved August 15, 2011)
Brand name: Propel
Generic name: mometasone furoate
Dosage form: Implant
Company: Intersect ENT, Inc.
Treatment for: Sinusitis
Propel (mometasone furoate) is a corticosteroid implant offering localized, controlled drug delivery for chronic sinusitis patients.
Development timeline for Propel
|Aug 15, 2011||Approval Intersect ENT Announces U.S. Food and Drug Administration Approval for Propel - First Drug Releasing Implant for Chronic Sinusitis Patients|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.